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Closure of Atrial Septal Defect and Patent 
Foramen Ovale, the Simple Way
Bernhard Meier, MD
A B S T R A C T
Catheter based closure of atrial septal defects was first described in 1974 but has only 
been used widely since the nineties. In 1992 the focus turned to closure of the patent 
foramen ovale which today is the most common atrial shunt closure. While the ma-
jority of centers advocate use of transesophageal or intracardiac echocardiographic 
guidance during implantation, fluoroscopy guided implantation is feasible, faster, 
cheaper, and more patient-friendly. Closure of a patent foramen ovale with an Amp-
latzer occluder (currently the preferred device) may take as little as 10 minutes with 
the possibility to return to full physical activity a couple of hours later. Complications 
are exceedingly rare (<1%). They include (about in the order of frequency) inguinal 
access problems, thrombus on the device, device embolization, cardiac perforation, 
erosion of the atrial wall by the device, or infection of the device. So far there are no 
reports of late complications although atrial fibrillation is one to be looked out for.
I N T R O D U C T I O N
A patent foramen ovale (PFO) is present in all babies at birth and about 30% 
of teenagers. The prevalence decreases to about 20% in octogenarians [1]. While a 
PFO is not considered a congenital heart defect, the atrial septal defect (ASD) is. Its 
most common form, the ASD II (secundum, located in or around the fossa ovalis and 
not involving atrial inflow structures or heart valves) constitutes the most common 
congenital heart defect together with the ventricular septal defect (VSD). It is pres-
ent in about 0.1 % of people and ranges from minute to huge (e.g., 4 cm). It may be 
multiple (Swiss cheese variety). An ASD secundum may lead to significant volume 
overload, resulting in enlargement of all heart chambers, save the left ventricle. Atrial 
fibrillation is its most common and feared complication occurring typically after the 
age of 40 years and being the number one reason (before heart failure) for mortality. 
Surgical closure of an ASD in adults failed to reduce the incidence of atrial fibrillation 
over the subsequent 30 years [2].
The first report of successful closure of an atrial septal defect dates back to 1974 
[3] preceding coronary angioplasty by more than 3 years. The introduction of the 
Rashkind atrial septal occluder in the eighties rekindled the interest in interatrial 
shunt closure that had lain dormant for 10 years, but catheter based ASD closure 
became commonplace only in the nineties with the introduction of self-centering 
devices, particularly the Amplatzer occluder (Figure 1). In 1992 a first report on PFO 
closure to prevent paradoxical stroke launched a new era [4]. While ASD closure will 
remain a fairly rare procedure, PFO closure has the potential to become the most 
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common procedure in interventional cardiology. Already, it 
accounts for about 10% of the interventional activity in some 
pioneering centers.
I N D I C A T I O N S
The smaller the ASD, the easier is catheter based closure 
with the PFO as the extreme example. Hence, it can be ar-
gued that all ASDs should be closed. The large ones because 
of their hemodynamic importance, the small ones and the 
PFOs because of their potential for paradoxical embolism and 
acknowledging their lack of intricacy for closing.
T E C H N I Q U E  O F  C L O S U R E  
I N T E R A T R I A L  S H U N T S  W I T H O U T  
E C H O C A R D I O G R A P H I C  G U I D A N C E  
A transesophageal echocardiography is the best base for 
the indication of closure of any interatrial shunt. With the 
Amplatzer ASD occluder (Figure 2) it is not necessary to 
measure the rims. The device will conform to virtually any 
anatomy, provided the defect is not too large (>40 mm) and 
an adequately sized device is selected. It is recommended to 
perform a stretched defect measurement with a sizing bal-
loon (compliant latex balloon with sizing markers) (Figure 
2). There is a small risk of enlarging the ASD by tearing a 
possibly very thin portion of the septum primum with the 
measuring balloon. However, this may avoid undersizing of the 
device, which could be unstable if implanted commensurate 
to an echocardiographically measured ASD without paying 
attention to the stability of the surrounding rim in the region 
of the septum primum. If the measuring balloon shows a clear 
waist and remains in stable position straddling the defect, an 
Amplatzer septal occluder about 20% larger than the mea-
sured diameter should be selected. If the balloon cannot be 
stabilized in the ASD, this indicates instability of part of the 
septal wall and mandates oversizing of the device compared 
with the balloon measurement by 30%-50%. 
Oversizing of the device has been advised against by a 
report analyzing the potential causes of the dreaded, albeit 
rare, device erosion due to friction of the device against the 
external atrial wall in contact with the pulsating aorta [5]. 
A contrary theory is that a somewhat oversized Amplatzer 
occluder will have rounder edges at least during the initial 
phase (Figure 2 C) and therefore should be less erosion-prone. 
During follow-up even generously sized Amplatzer occluders 
will flatten down (Figure 3).
FIGURE 1. Dedicated atrial septal defect (ASD) closure devic-
es. The self-centering during and after implantation is attempt-
ed by strings in the StarFlex device (NMT Medical, Boston, 
Massachusetts, U.S.A.), by flexible wires in the Sideris COD 
device (Sideris, Athens, Greece), by a waist diameter com-
mensurate with the defect in the Amplatzer Septal Occluder 
(AGA, Minneapolis, Minnesota, U.S.A.), and by a foam ring in 
the Intrasept ASD closure device (Cardia Inc. Burnsville, Min-
neapolis, U.S.A.). The only device used widely is the Amplatzer 
Septal Occluder.
FIGURE 2. A. Transthoracic echocardiography in a 41-year-old 
woman showing an ASD II projected in the view used for 
fluoroscopy during catheter based device closure. The left to 
right shunt is made visible by Doppler color flow. B. Measuring 
balloon across the defect yielding a diameter of 20 mm. The 
top 2 calibration markers are separated by 10 mm. C. Control 
hand injection of a small amount of contrast medium through 
the introducer sheath (9 French) after implantation of a 30 mm 
Amplatzer Occluder. The position can be ascertained without 
need for echocardiography. D. Corresponding transthoracic 
echocardiographic view of the device 1 day later showing no 
residual shunt. LA = left atrium; RA = right atrium.
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If the intervention was based on a state-of-the-art trans-
esophageal echocardiography, it is unlikely to miss additional 
ASDs by not using echocardiography during the intervention. 
Figure 4 demonstrates the case of a 27-year-old woman who 
wound up with 4 devices after 3 additional ASDs had been 
missed during closure of a presumed single ASD (report of 
a pre-intervention transesophageal echocardiogram) at the 
first intervention. During the second intervention, two ASDs 
were closed using transesophageal echocardiography. During 
follow-up, it turned out that an additional sizable ASD had 
been missed which was closed in a final third intervention, 
again without echocardiographic guidance. The septum was 
completely closed at follow-up. 
The technique for PFO closure is analogous but even more 
simple. Figure 5 explains some salient features. Of the large 
variety of devices available for that purpose (Figure 6), only 3 
have collected significant clinical experience (Amplatzer PFO 
occluders, PFOStar/TransSeptal devices, and the CardioSeal/
StarFlex devices).
The key feature for correctly placing an Amplatzer PFO 
occluder (or any occluder for that matter) without echocar-
diographic guidance is an ideal angiographic projection com-
bined with injection of contrast medium (performed by hand 
through the introducer sheath) where pertinent (Figure 7). 
If the device fails to straddle the septum secundum (negative 
Pacman sign), this will not necessary lead to embolization for 
the reasons explained in figure 8 but it will increase the risk 
FIGURE 3. Flattening of a slightly oversized Amplatzer oc-
cluder over time. Left panel: Situation after implantation. A 
hand injection of contrast medium into the right atrium depicts 
the correct position equally well as an intraprocedural echo-
cardiogram. The neck of the intentionally oversized Amplatzer 
Occluder is slightly constricted, keeping the disks in a some-
what rounded shape. Right panel: 18 months later the device 
has flattened down and the neck has fully expanded. 
FIGURE 4. Quadruple ASD closure in a 27-year-old woman. 
A. Balloon measuring of a fourth large ASD missed during two 
previous interventions (second one done with transesophageal 
echocardiographic guidance). B. 4 Amplatzer septal occluders 
nestled in the interatrial septum. The right atrium is opaci-
fied by contrast medium injection into the right atrium (RA). 
C. Levophase of the contrast medium injection into the RA 
with opacification of the left atrium (LA). D. Transesophageal 
echocardiogram before the last device implantation showing 
significant left-to-right shunt by color Doppler next to the 
aorta. E. Transesophageal echocardiographic follow-up at 6 
months showing good position of all 4 devices. There was no 
residual shunt.
FIGURE 5. Left panel: Transesophageal echocardiography 
projected in analogy to the usual fluoroscopic aspect depicted 
graphically in the right panel. The PFO is a gap between the 
thick muscular septum secundum (SS) and the flap like thin 
septum primum (SP) which can move away from the SS towards 
the left atrium (arrow) (LA). The right atrium (RA) is filled 
with echocardiographic contrast bubbles which find access to 
the LA (top) after a sustained Valsalva maneuver while the 
blood is rushing back to the RA with the LA still underfilled. 
This mechanism is prevented by device closure (bottom). IVC 
= inferior vena cava; LV = left ventricle; PV = pulmonary vein; 
RV = right ventricle; SVC = superior vena cava.
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for a residual shunt.
C O N C L U S I O N
The advantages and disadvantages of using echocardio-
graphic guidance for atrial shunt closure are summarized in 
Table 1. While a number of centers have already abandoned 
echocardiography during PFO closure for the simplicity of 
this procedure and its high number of cases mandating a 
frugal approach, echocardiographic guidance is still deemed 
mandatory for ASD closure in general. My experience with 
ASD closures with and without echocardiographic assistance 
proves that judicious and intelligent exploitation of fluoros-
FIGURE 6. Currently available devices for PFO closure in order of their user-friendliness and performance. A. Amplatzer PFO Occluder 
device, available in 5 sizes all with a thin, flexible and extendible neck: 25 mm (right disk 25 mm, left disk 18 mm, standard device); 35 mm 
(right disk 35 mm, left disk 22 mm); 18 mm (both disks 18 mm); Cribriform 25 mm (both disks 25 mm); Cribriform 35 mm (both disks 35 
mm), (AGA, Minneapolis, Minnesota, U.S.A.), B. Solysafe (Carag, Baar, Switzerland), C. TransSeptal device (Cardia Inc. Burnsville, Min-
neapolis, U.S.A.), D. Premere device (Velocimed, Maple Grove, Minneapolis, U.S.A.), E. StarFlex device (formerly CardioSeal) (NMT 
Medical, Boston, Massachusetts, U.S.A.), F. Helex Septal Occluder device (Gore Newark, Delaware, U.S.A.), G. Sideris Buttoned Occluder 
device (Sideris, Athens, Greece).
copy obviates the need for simultaneous echocardiography 
during any Amplatzer device implantation. Other devices 
are more cumbersome to implant but still do not mandate 
echocardiography either. 
Hence, fluoroscopically guided closure of PFOs and ASDs 
is not only feasible but safe and equally effective as echo-
cardiographically guided techniques. It affords considerable 
economical and comfort advantages. Table 2 recapitulates the 
important steps of the technique.
Interventional cardiologists embarking on interatrial shunt 
closure should start with the PFO using the 35 mm Amplatzer 
PFO Occluder for the initial cases. This is by far the easiest-to-
use device with a good record of permanent occlusion. Once 
they feel comfortable with PFO closures using the standard 
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TABLE 1. Advantages and disadvantages of echocardio-
graphical guidance during percutaneous interatrial shunt 
closure
Advantages
- Smaller risk of misplacement or suboptimal placement
- Smaller risk of missing additional shunts
- Immediate information about residual shunt
- No need for contrast medium injections
- Shared responsibility between interventional cardiologist and 
echocardiographer 
Disadvantages
- Need for general anesthesia (perhaps even intubation) or at
 least deep sedation
- Risk of aspiration with esophageal intubation in supine position
- Increased cost for additional manpower or use of intracardiac 
(disposable) echocardiographic equipment
- Significantly prolonged procedure time and laboratory
 occupation
TABLE 2. Technique of percutaneous interatrial shunt 
closure with Amplatzer devices
- Outpatient procedure
- No echocardiographic guidance
- Local anesthesia at right groin
- Access through right femoral vein
- 0.035 inch (exchange) wire
- Multipurpose catheter to pass defect unless wire crosses
 spontaneously 
- Balloon gauging (18 mm or 24 mm in small children, 34 mm in
 adults)
- 6-12 French sheath according to occluder size (9 French for PFO)
- Right atrial contrast medium injections (by hand, left anterior
 oblique and cranial view)
- Antibiotics (1 - 3 doses)
- Unrestricted physical activity after a few hours
- Acetylsalicylic acid 100 mg for 5 months
- Clopidogrel 75 mg for 1 month
- Prophylaxis against endocarditis (for 3 - 6 months)
- TEE at about 6 months (1 month after stopping platelet
 inhibitors)
FIGURE 7. Pacman sign for correct placement of PFO occlud-
ers. The Pacman sign consists of a V-shaped configuration of 
the left and right atrial disks, respectively, when viewed in a 
projection (usually left anterior oblique view with cranial tilt) 
showing the device in perfect profile. The septum secundum 
(SS) being thick and muscular separates the left cranial part of 
the device much more than the septum primum (SP) being thin 
and flexible. The top panel shows the anatomy by transesopha-
geal echocardiography (left) and by angiography (right) using 
the arcade figure Pacman as analogy. The bottom panel shows 
an incorrect placement (left, 18 mm Amplatzer PFO Occluder) 
where the septum secundum is not between the two disks and 
the correct placement of a 25 mm Amplatzer PFO Occluder in 
the same patient (right). LA = left atrial; RA = right atrium.
device (25 mm Amplatzer Occluder) they can then move on 
to ASD closures, starting first with small defects (20 mm or 
smaller). Closure of larger defects (20 mm to 40 mm) should 
be reserved for subspecialized accomplished interventional 
cardiologists and percutaneous closure of even larger defects 
is currently not possible and may never be. 
FIGURE 8. Schematic explanation (view from the right atrium) 
for the Pacman sign and the situation if it is not honored. The 
left panel shows the anatomy with a small cranial sector where 
the septum secundum is thick. The middle panel shows the cor-
rect position of the right atrial disk. The right panel shows the 
incorrect position where the thick part of the septum secundum 
is not between the disks but to the right of the right atrial disk. 
It is apparent that the device will not embolize in spite of the 
incorrect position because the prolapse of the right atrial disk 
into the left atrium encompasses only a small sector of the cir-
cumference. SS = septum secundum; SP = septum primum.
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